AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Enhanced CD8+ CTL formation for Adoptive Cell Therapies

       
Detailed Technology Description
Compositions and methods that direct ex vivo cultured T cells to a Cytotoxic T lymphocyte (CTL) fate in a T helper cell independent manner.
*Abstract

A method for enhanced ex vivo stimulation of cytotoxic CD8+ T lymphocytes (CTL), independent of CD4+ T helper cells, for improved Adoptive Cell Therapy (ACT). Inhibiting tyrosine phosphatase PTPN2 achieves greatly enhanced T-cell stimulation, compatible with the challenging ex vivo activation of tumor infiltrating lymphocytes.
• Method to stimulate ex vivo CTL populations for ACT in a T-helper cell independent manner
• Compatible with the ex vivo reinvigoration of 'tolerised' T-cells or tumour antigen specific CAR-T cells
• 'Proof of Mechanism' in vivo efficacy
• Potential use in single agent and combination therapy applications
Country/Region
USA

For more information, please click Here
Mobile Device